567 related articles for article (PubMed ID: 31651363)
21. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
Krönig H; Hofer K; Conrad H; Guilaume P; Müller J; Schiemann M; Lennerz V; Cosma A; Peschel C; Busch DH; Romero P; Bernhard H
Int J Cancer; 2009 Aug; 125(3):649-55. PubMed ID: 19444908
[TBL] [Abstract][Full Text] [Related]
22. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
23. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
[TBL] [Abstract][Full Text] [Related]
24. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
Jakka G; Schuberth PC; Thiel M; Held G; Stenner F; Van Den Broek M; Renner C; Mischo A; Petrausch U
Anticancer Res; 2013 Oct; 33(10):4189-201. PubMed ID: 24122982
[TBL] [Abstract][Full Text] [Related]
25. Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.
Camisaschi C; Renne SL; Beretta V; Rini F; Spagnuolo RD; Tuccitto A; Podda MG; Parmiani G; Rivoltini L; Collini P; Castelli C; Luksch R
BMC Cancer; 2018 Oct; 18(1):983. PubMed ID: 30326856
[TBL] [Abstract][Full Text] [Related]
26. First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.
Pollack SM; Lu H; Gnjatic S; Somaiah N; O'Malley RB; Jones RL; Hsu FJ; Ter Meulen J
J Immunother; 2017 Oct; 40(8):302-306. PubMed ID: 28891906
[TBL] [Abstract][Full Text] [Related]
27. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
28. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Matsuzaki J; Gnjatic S; Mhawech-Fauceglia P; Beck A; Miller A; Tsuji T; Eppolito C; Qian F; Lele S; Shrikant P; Old LJ; Odunsi K
Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7875-80. PubMed ID: 20385810
[TBL] [Abstract][Full Text] [Related]
29. Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy.
Schroeder BA; Black RG; Spadinger S; Zhang S; Kohli K; Cao J; Mantilla JG; Conrad EU; Riddell SR; Jones RL; Yee C; Pollack SM
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32269142
[TBL] [Abstract][Full Text] [Related]
30. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
31. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
32. Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.
Zhang S; Kohli K; Black RG; Yao L; Spadinger SM; He Q; Pillarisetty VG; Cranmer LD; Van Tine BA; Yee C; Pierce RH; Riddell SR; Jones RL; Pollack SM
Cancer Immunol Res; 2019 Aug; 7(8):1237-1243. PubMed ID: 31171504
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy of sarcomas with modified T cells.
Mahalingam P; Julve M; Huang P; Furness AJS; Pollack SM; Jones RL
Curr Opin Oncol; 2022 Jul; 34(4):362-370. PubMed ID: 35837706
[TBL] [Abstract][Full Text] [Related]
34. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
35. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
[TBL] [Abstract][Full Text] [Related]
36. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
Moon EK; Ranganathan R; Eruslanov E; Kim S; Newick K; O'Brien S; Lo A; Liu X; Zhao Y; Albelda SM
Clin Cancer Res; 2016 Jan; 22(2):436-47. PubMed ID: 26324743
[TBL] [Abstract][Full Text] [Related]
37. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
Puig-Saus C; Parisi G; Garcia-Diaz A; Krystofinski PE; Sandoval S; Zhang R; Champhekar AS; McCabe J; Cheung-Lau GC; Truong NA; Vega-Crespo A; Komenan MDS; Pang J; Macabali MH; Saco JD; Goodwin JL; Bolon B; Seet CS; Montel-Hagen A; Crooks GM; Hollis RP; Campo-Fernandez B; Bischof D; Cornetta K; Gschweng EH; Adelson C; Nguyen A; Yang L; Witte ON; Baltimore D; Comin-Anduix B; Kohn DB; Wang X; Cabrera P; Kaplan-Lefko PJ; Berent-Maoz B; Ribas A
Clin Cancer Res; 2019 Feb; 25(3):1000-1011. PubMed ID: 30409823
[TBL] [Abstract][Full Text] [Related]
38. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
[TBL] [Abstract][Full Text] [Related]
39. A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.
Nowicki TS; Berent-Maoz B; Cheung-Lau G; Huang RR; Wang X; Tsoi J; Kaplan-Lefko P; Cabrera P; Tran J; Pang J; Macabali M; Garcilazo IP; Carretero IB; Kalbasi A; Cochran AJ; Grasso CS; Hu-Lieskovan S; Chmielowski B; Comin-Anduix B; Singh A; Ribas A
Clin Cancer Res; 2019 Apr; 25(7):2096-2108. PubMed ID: 30573690
[TBL] [Abstract][Full Text] [Related]
40. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
Khong HT; Yang JC; Topalian SL; Sherry RM; Mavroukakis SA; White DE; Rosenberg SA
J Immunother; 2004; 27(6):472-7. PubMed ID: 15534491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
